Suppr超能文献

CD4+ 和 CD8+ T 细胞对 JC 病毒反应在进行性多灶性白质脑病(PML)和伴有免疫重建炎症综合征的 PML 患者结局中的作用。

Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome.

机构信息

Division of NeuroVirology, Beth Israel Deaconess Medical Center, E/CLS-1005, 330 Brookline Avenue, Boston, MA 02215, USA.

出版信息

J Virol. 2011 Jul;85(14):7256-63. doi: 10.1128/JVI.02506-10. Epub 2011 May 4.

Abstract

Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the brain caused by JC virus (JCV). To assess the role of CD4(+) and CD8(+) T-cells against JCV in the clinical outcome of PML and PML in the setting of immune reconstitution inflammatory syndrome (IRIS), we tested gamma interferon (IFN-γ) response by enzyme-linked immunosorbent spot (ELISpot) and intracellular cytokine staining (ICS) in 117 subjects, including 66 PML patients with different clinical outcomes. Both assays were concordant and demonstrated that the cellular immune response against JCV is associated with better clinical outcome. PML survivors had an early CD8(+) T-cell response more frequently than PML progressors (100% versus 27.3%; P = 0.001), while only a trend was observed for the early CD4(+) T-cell response between these two groups (80% versus 45.5%; P = 0.18). Although IRIS itself was more frequent in the PML survivor group, there was no difference in IFN-γ-producing CD4(+) and CD8(+) T-cells between IRIS and non-IRIS PML patients, suggesting that T-cells expressing other cytokines likely have a role in the immunopathogenesis of IRIS. ELISpot and ICS assays are useful prognostic markers of PML evolution and may help in the clinical management of these patients.

摘要

进行性多灶性白质脑病(PML)是一种由 JC 病毒(JCV)引起的严重脑脱髓鞘疾病。为了评估 CD4(+)和 CD8(+)T 细胞对 PML 和免疫重建炎症综合征(IRIS)背景下 PML 中 JCV 的作用,我们通过酶联免疫斑点(ELISpot)和细胞内细胞因子染色(ICS)测试了 117 名受试者(包括 66 名具有不同临床结局的 PML 患者)的γ干扰素(IFN-γ)反应。两种检测方法均一致表明,针对 JCV 的细胞免疫反应与更好的临床结局相关。PML 幸存者比 PML 进展者更频繁地出现早期 CD8(+)T 细胞反应(100%比 27.3%;P = 0.001),而这两组之间早期 CD4(+)T 细胞反应仅呈趋势(80%比 45.5%;P = 0.18)。尽管 IRIS 本身在 PML 幸存者组中更为常见,但 IFN-γ 产生的 CD4(+)和 CD8(+)T 细胞在 IRIS 和非 IRIS PML 患者之间没有差异,这表明表达其他细胞因子的 T 细胞可能在 IRIS 的免疫发病机制中发挥作用。ELISpot 和 ICS 检测是 PML 进展的有用预后标志物,可能有助于这些患者的临床管理。

相似文献

5
Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy.
J Neurovirol. 2002 Dec;8 Suppl 2:59-65. doi: 10.1080/13550280290167894.
10
Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?
Neurology. 2012 Dec 4;79(23):2258-64. doi: 10.1212/WNL.0b013e3182768983. Epub 2012 Nov 21.

引用本文的文献

1
JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab.
Front Neurol. 2025 Aug 4;16:1584083. doi: 10.3389/fneur.2025.1584083. eCollection 2025.
4
Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy.
Cell Rep Med. 2024 Jul 16;5(7):101622. doi: 10.1016/j.xcrm.2024.101622. Epub 2024 Jun 24.
5
Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy in China.
J Neurovirol. 2023 Dec;29(6):692-698. doi: 10.1007/s13365-023-01180-w. Epub 2023 Oct 28.
6
Polyomavirus Wakes Up and Chooses Neurovirulence.
Viruses. 2023 Oct 18;15(10):2112. doi: 10.3390/v15102112.
8
Progressive Multifocal Leukoencephalopathy Initially Suspected As Brain Relapse From Classical Hodgkin's Lymphoma.
Cureus. 2023 Aug 23;15(8):e44000. doi: 10.7759/cureus.44000. eCollection 2023 Aug.
10
Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors.
Ann Neurol. 2023 Feb;93(2):257-270. doi: 10.1002/ana.26512. Epub 2022 Oct 17.

本文引用的文献

1
Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy.
J Neurol Neurosurg Psychiatry. 2010 Nov;81(11):1288-91. doi: 10.1136/jnnp.2009.179002. Epub 2010 Aug 14.
3
Neurological complications of immune reconstitution in HIV-infected populations.
Ann N Y Acad Sci. 2010 Jan;1184:106-20. doi: 10.1111/j.1749-6632.2009.05111.x.
4
Determinants of survival in progressive multifocal leukoencephalopathy.
Neurology. 2009 Nov 10;73(19):1551-8. doi: 10.1212/WNL.0b013e3181c0d4a1.
5
Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression.
J Neurol Neurosurg Psychiatry. 2010 Mar;81(3):247-54. doi: 10.1136/jnnp.2009.187666. Epub 2009 Oct 14.
6
Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
N Engl J Med. 2009 Sep 10;361(11):1081-7. doi: 10.1056/NEJMoa0810316.
7
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
N Engl J Med. 2009 Sep 10;361(11):1075-80. doi: 10.1056/NEJMoa0810257.
8
Asymptomatic reactivation of JC virus in patients treated with natalizumab.
N Engl J Med. 2009 Sep 10;361(11):1067-74. doi: 10.1056/NEJMoa0904267.
9
Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm.
Curr Opin HIV AIDS. 2009 May;4(3):206-14. doi: 10.1097/COH.0b013e328329c68c.
10
Identification and characterization of mefloquine efficacy against JC virus in vitro.
Antimicrob Agents Chemother. 2009 May;53(5):1840-9. doi: 10.1128/AAC.01614-08. Epub 2009 Mar 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验